Salvage Treatment With Lenalidomide and Dexamethaosne (LEN-DEX) in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Salvage Treatment With Lenalidomide and Dexamethaosne(LEN-DEX) in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Sponsor: Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte
Listed as NCT00786851, this PHASE2 trial focuses on MANTLE CELL LYMPHOMA and remains completed. Sponsored by Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte, it has been updated 7 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jun 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jun 2023 [monthly]
Completed PHASE2
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Jul 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte
- Fondazione Italiana Linfomi - ETS
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alessandria, Italy , Aviano (PN), Italy , Brescia, Italy , Cagliari, Italy , Milan, Italy , Pavia, Italy , Reggio Calabria, Italy , Reggio Emilia, Italy , Roma, Italy , Rozzano (MI), Italy and 5 more locations